Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Thanks Chizzy. That is interesting. Interesting partly because it is wrong. I have seen a few articles now perpetuating the wrong idea that Eroxon contains GTN. A lot of this article focusses on GTN, which is just not an ingredient in Eroxon. There has been some lazy journalism around this. Proably not important in the bigger scheme of things but expected better from Forbes. It misses the important point about how Eroxon developed out of earlier products. Med2005 contained GTN and what we now have in Eroxon was the 'placebo' in a trial of Med2005, and performed just as well. GTN has side effects , including headaches, nausea etc, and Eroxon does not . Good that Eroxon is getting a lot of publicity, but people need accurate information about what it actually is......
I don't think that we need to be concerned with some reviews on certain UK websites. You can't hold back the tide.The product is clearly selling across European markets and here in the UK. Licenses are in place for many parts of the world and FDA approval round the corner. The current gripes of a few individuals are really going to make no meaningful difference to the long term success or otherwise of FUTURA.
8 June 2023
Futura Medical plc
("Futura" or the "Company")
Futura Medical Announces Investor Seminar
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, is
pleased to announce that it will be hosting an Investor Seminar on the 22 June
2023 in London for analysts and institutional investors. Following the
Investor Seminar, an Investor Meet Company meeting will be held for Retail
Investors on Monday the 26 June.
The Investor Seminar follows a milestone year to date following the UK launch
on the 18 April 2023 of MED3000 under the brand name Eroxon® with Cooper
Consumer Health, its EU and UK distribution partner, and online launches in
Europe and in retail pharmacies in Belgium.
The Investor Sseminar will feature presentations from Futura as well as
eminent Key Opinion Leaders (KOLs) Dr Jeff Foster, BSc, (Hons), MB ChB, DRCOG,
MRCGP, men's health specialist and book author and Dr Janine David, FECSM, GP
who specialises in Men and Women's sexual health and will close with a
presentation by Mark Berkhout, International Marketing Director for Cooper
Consumer Health & Jon Connolly Marketing Director Ceuta Healthcare
For further information on the Investor Seminar, or to register your interest,
please contact Optimum Strategic Communications at
futuramedical@optimumcomms.com. Further information will be made available
closer to the event.
A recording will be made available through a webcast which can be accessed via
the investor section of the Futura website shortly after the event. No new
material disclosures will be made at the event.
The Retail Investor event is scheduled for Monday 26 June at 10:00am with
Investor Meet Company. Retail Investors can sign up to Investor Meet Company
for free via www.investormeetcompany.com (http://www.investormeetcompany.com)
.
It is given prominence in my local Boots with a big sign 'New and only at Boots'.
Eroxon has now appeared for sale at this site :https://www.menschem.co.uk/product/eroxon-erectile-dysfunction-treatment-gel/
Appears to be a Leicester based pharmacy
Only one review posted so far- very negative.
This perception about buys and sells comes up so often on bulletin boards. Mark Simpson did a useful piece about stock market myths recently on Stockopedia
"Myth 1 - They’ve marked my buy as a sell
Everyone likes to track their impact on the world, so investors often look for their buy or sell to show up in the reported trades. In such feeds, transactions are allocated to a buy or sell column. Sometimes, a share purchase will be marked as a sale, and vice versa. When this happens, some investors believe it has been intentionally misreported to give a false picture of the underlying supply and demand.
The Truth: Every trade is a buy and a sell. Investors are trading either directly with another investor on the order book or with a Market Maker. The information the exchange publishes is just the time, price, volume and a code to indicate the type of trade. It is data processors that categorise these trades into buys or sells. They do this simply using the published bid and ask at the time of the transaction. Any trade price below the mid-price is marked as a sell and above as a buy. Investors who bought shares below the published mid-price should be thankful that they purchased stock cheaply and not worried that reporting has been manipulated."
Current wording at Eroxon.com suggesting not yet availableEroxon® has received CE mark and UKCA mark approval as a medical device. This will enable Eroxon® to be marketed across the EU and UK. Eroxon® is expected to be available to buy during the first half of 2023. Approval is being sought in a rapid time frame in many countries around the world.Futura has granted Cooper Consumer Health SAS ("Cooper") exclusive marketing and distribution rights for Eroxon® throughout the European Economic Area including the United Kingdom and Switzerland. All product or sales enquiries will be handled directly by Cooper.Contact details can be found at www.cooperconsumerhealth.euPlease check this website regularly for updates.However, current wording at https://hcp.eroxon.co.uk/hcpentry/ed-treatmentsAvailability and regulatory informationEroxon’s novel treatment for ED is already available without prescription in the EU and UK and is expected to receive a similar regulatory status in many other parts of the world. Our commercial partner for this region, Cooper Consumer Health, has already launched the product in Belgium with further launches expected in Europe this year. Eroxon is also available online via Amazon and Apotheke on their European platformsThis is confusing and inconsistent. Two different messages and where is it available in the UK????Surely all of the company focus is on this launch? Yet they can't get a consistent message out. They had one job!.......
I have signed up for the webinar. Will be interesting to hear the discussion and report back.
Yes, I think you are correct. Up to just a couple of days ago the Farmaline site was showing delivery expected 27th MArch. That message has now been removed. Does this mean delays to launch? Who knows?
Yes, it is clear on the Farmaline website that they expect stock on 27th March.
Farmaline now suggesting late March
"New! Expected from March 27, 2023.
Eroxon® Stimgel is a clinically proven treatment for erectile dysfunction in men aged 18 years and older. Helps get an erection within 10 minutes."
The details of the RNS suggest that it is a poster presentation only. This means there will not be a presentation to listen to- literally just a poster on display for people to look at, with someone there to answer any questions. A bit disappointing that they have not managed to get a presentation slot at the conference. Posters are usually for less important or detailed studies. We think and hope that this is hugely important!
RNS this morning:
Futura Medical to present MED3000 FM71 data at the European Society for Sexual Medicine Congress 2023
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology, with a current focus on sexual health and pain, today announces that it will be presenting data on its lead product MED3000 for the treatment of erectile dysfunction ("ED") at the European Society for Sexual Medicine (ESSM) Congress in Rotterdam, The Netherlands on the 16-18 February 2023.
Yes. No real news in the RNS so not surprised there is little movement in sp. I wonder if they put it out only because people here were starting to notice the sales activity at Farmaline?
Yes.Eroxon ‘popping up’ on websites now in Turkey, Vietnam and others as a product for sale. Lift off imminent.
https://www.futuramedical.com/investor-centre/videos-and-webcasts/videos/
In the video two respected sexual medicine experts ( from the US and Brazil) both suggesting that Eroxon could become the 'first line' treatment. They also seem to assume confidently that it will be available OTC in the states, and all of the signs now seem to be that the FDA approval will be forthcoming.
Great news. Our patience should soon be rewarded. All of the important pieces are falling into place, and this confirmatory trial is really good news in terms of the US pathway.
Whilst we all wait for a successful product launch and growing sales, I can't decide whether the tendentious ramblings of dictionary.com-browse-idiot are entertaining or just tiresome. Mainly the latter but it is the responses he gets which provide the entertainment on here.
We found love
So don't fight it
Life is a rollercoaster
Just gotta ride it
I need you, FUM
Links Irrelevant And Meaningless. Blatantly Offering Old Tired Halftruths